The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 17, 2020

Filed:

Jun. 29, 2018
Applicant:

University of Maryland, College Park, Waldorf, MD (US);

Inventors:

Lai-Xi Wang, Ellicott City, MD (US);

Xin Tong, College Park, MD (US);

Tiezheng Li, Columbia, MD (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); C12R 1/46 (2006.01); C07K 1/04 (2006.01); C07K 1/36 (2006.01); C07K 1/02 (2006.01); C07K 1/107 (2006.01); A61K 47/61 (2017.01); A61K 47/54 (2017.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 9/24 (2006.01); C12P 21/00 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 47/549 (2017.08); A61K 47/61 (2017.08); A61K 47/6803 (2017.08); C07K 1/02 (2013.01); C07K 1/045 (2013.01); C07K 1/1077 (2013.01); C07K 1/36 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); C12N 9/2402 (2013.01); C12P 21/005 (2013.01); C12R 1/46 (2013.01); A61K 9/0019 (2013.01); C07K 2317/10 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C12Y 302/01096 (2013.01);
Abstract

The present invention provides for recombinant Endo-S mutants (named Endo-S glycosynthases) that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a fucosylated or nonfucosylated GlcNAc-IgG acceptor. As such, the present invention allows for the synthesis and remodeling of therapeutic antibodies thereby providing for certain biological activities, such as, prolonged half-life time in vivo, less immunogenicity, enhanced in vivo activity, increased targeting ability, and/or ability to deliver a therapeutic agent.


Find Patent Forward Citations

Loading…